Publication | Closed Access

Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group

Breast OncologyOncologyMedicineWeekly PaclitaxelBreast CancerFirst-line TreatmentCarboplatin Plus BevacizumabCancer TreatmentPharmacologyMolecular Oncology